儿童甲状腺病变中致癌基因改变的分子检测
该回顾性横断面研究对115份儿童甲状腺病变存档样本行多重定性PCR及珠阵列流式细胞术检测17种分子标志物,发现32/68(47%)恶性标本存在突变,RAS或PAX8/PPARG仅见于滤泡状癌和滤泡型乳头状癌,BRAF为经典型乳头状癌最常见突变,RET/PTC仅见于弥漫硬化型乳头状癌。
要点
- 32/68(47%)恶性标本检出突变,33例有基因改变者中32例为恶性。
- RAS或PAX8/PPARG仅见于滤泡状癌和滤泡型乳头状癌。
- BRAF为经典型乳头状癌最常见突变(12/17;71%),未预测更具侵袭性表型。
核心结论
- 33例有基因改变的结节中32例为恶性。
- RAS突变最常与滤泡状癌相关,RET/PTC重排与弥漫硬化型乳头状癌及侵袭性滤泡型乳头状癌相关,BRAF与经典型乳头状癌相关。
- 结果提示突变分析对儿童结节的手术方式选择可能有临床指导作用。
研究设计与样本
- 回顾性横断面评估115份存档样本,包括47例良性(29例滤泡状腺瘤、11例弥漫性增生、4例甲状腺炎、3例多结节性甲状腺肿)、6例滤泡状甲状腺癌、24例滤泡型乳头状甲状腺癌、27例经典型乳头状甲状腺癌、8例弥漫硬化型乳头状甲状腺癌及3例其他乳头状甲状腺癌。
- 分子检测采用多重定性聚合酶链反应后行珠阵列流式细胞术。
- 分析致癌基因结果与年龄、性别、组织学、淋巴结转移及甲状腺内播散的关系。
主要发现
- 17种分子标志物中检出突变:滤泡状甲状腺癌2/6(33%)、滤泡型乳头状甲状腺癌8/24(33%)、经典型乳头状甲状腺癌17/27(63%)、弥漫硬化型乳头状甲状腺癌4/8(50%)。
- RAS或PAX8/PPARG突变仅见于滤泡状甲状腺癌和滤泡型乳头状甲状腺癌。
- BRAF为经典型乳头状甲状腺癌最常见突变(12/17;71%),RET/PTC为弥漫硬化型乳头状甲状腺癌唯一相关突变。
- 恶性标本中32/68(47%)检出突变,1例滤泡状腺瘤PAX8/PPARG阳性。
- 儿童病变基因改变相对分布与成人相似;儿童经典型乳头状甲状腺癌中BRAF突变未预测更具侵袭性表型。
关键数值与推荐
- RAS或PAX8/PPARG突变仅见于滤泡状甲状腺癌和滤泡型乳头状甲状腺癌。
- BRAF为经典型乳头状甲状腺癌最常见突变(12/17;71%)。
- RET/PTC为弥漫硬化型乳头状甲状腺癌唯一相关突变。
临床怎么用
- 作者认为突变分析对儿童结节的手术方式选择可能有临床指导作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid nodules are less common in pediatric patients (i.e., those ≤18 years) than they are in adults. The Bethesda System for Reporting Thyroid Cytopathology allows for individual risk stratification, but a significant number of nodules are indeterminate. Incorporating gene mutation panels and gene expression classifiers may aid in preoperative diagnosis. The overall aim of this study was to assess the prevalence of oncogene alterations in a representative pediatric population and across a broad-spectrum of thyroid tumor diagnoses. METHODS: This was a retrospective cross-sectional evaluation of 115 archived samples, including: 47 benign (29 follicular adenoma, 11 diffuse hyperplasia, four thyroiditis, and three multinodular goiter), six follicular thyroid carcinomas (FTC), 24 follicular variant of papillary thyroid carcinomas (fvPTC), 27 classic variant of PTC (cPTC), eight diffuse sclerosing variant of PTC (dsvPTC), and three other PTC. Molecular testing was performed by multiplex qualitative polymerase chain reaction followed by bead array cytometry. Oncogene results were analyzed for association with age, sex, histology, lymph node metastasis, and intrathyroidal spread. RESULTS: A mutation in one of the 17 molecular markers evaluated was found in: 2/6 (33%) FTC, 8/24 (33%) fvPTC, 17/27 (63%) cPTC, and 4/8 (50%) dsvPTC. Mutations in RAS or PAX8/PPARG were exclusive to FTC and fvPTC. BRAF was the most common mutation in cPTC (12/17; 71%), and RET/PTC was the only mutation associated with dsvPTC. Overall, a mutation was found in 32/68 (47%) malignant specimens, with a single follicular adenoma positive for PAX8/PPARG. The relative distribution of gene alterations in pediatric lesions was similar to adults. The presence of a BRAF mutation in pediatric cPTC did not predict a more invasive phenotype. CONCLUSIONS: Of 33 nodules with genetic alterations, 32 were malignant. Mutations in RAS were most frequently associated with FTC, RET/PTC rearrangements with dsvPTC, and invasive fvPTC, and BRAF with cPTC. These results suggest a clinical role for mutational analysis of pediatric nodules to guide the surgical approach.
引用
- Mostoufi-Moab S, Labourier E, Sullivan L, et al. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions. Thyroid. 2017. PMID: 29108474. doi:10.1089/thy.2017.0059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。